Key result
Bucindolol reduced mortality by 38% compared to placebo in heart failure patients homozygous for the beta1-Arg-389 polymorphism, while Gly-389 carriers derived no survival benefit.
RCT (n=1,040)
placebo-controlled
randomized
Yes
Answers are grounded in this paper and cite their sources.
Supports genotype-guided bucindolol use in select HF patients; extends RCT evidence for beta1AR polymorphism effects on beta-blocker response.
Heterogeneity of heart failure (HF) phenotypes indicates contributions from underlying common polymorphisms. We considered polymorphisms in the beta(1)-adrenergic receptor (beta(1)AR), a beta-blocker target, as candidate pharmacogenomic loci. Transfected cells, genotyped human nonfailing and failing ventricles, and a clinical trial were used to ascertain phenotype and mechanism. In nonfailing and failing isolated ventricles, beta(1)-Arg-389 had respective 2.8 +/- 0.3- and 4.3 +/- 2.1-fold greater agonist-promoted contractility vs. beta(1)-Gly-389, defining enhanced physiologic coupling under relevant conditions of endogenous expression and HF. The beta-blocker bucindolol was an inverse agonist in failing Arg, but not Gly, ventricles, without partial agonist activity at either receptor; carvedilol was a genotype-independent neutral antagonist. In transfected cells, bucindolol antagonized agonist-stimulated cAMP, with a greater absolute decrease observed for Arg-389 (435 +/- 80 vs. 115 +/- 23 fmol per well). Potential pathophysiologic correlates were assessed in a placebo-controlled trial of bucindolol in 1,040 HF patients. No outcome was associated with genotype in the placebo group, indicating little impact on the natural course of HF. However, the Arg-389 homozygotes treated with bucindolol had an age-, sex-, and race-adjusted 38% reduction in mortality (P = 0.03) and 34% reduction in mortality or hospitalization (P = 0.004) vs. placebo. In contrast, Gly-389 carriers had no clinical response to bucindolol compared with placebo. Those with Arg-389 and high baseline norepinephrine levels trended toward improved survival, but no advantage with this allele and exaggerated sympatholysis was identified. We conclude that beta(1)AR-389 variation alters signaling in multiple models and affects the beta-blocker therapeutic response in HF and, thus, might be used to individualize treatment of the syndrome.
No takes yet. Share an insight, caveat, or question.
Liggett et al. (2006) conducted an RCT in Heart failure (n=1,040). Bucindolol vs. Placebo was evaluated on Mortality (HR 0.62, 95% CI 0.40-0.96, p=0.03). Bucindolol reduced mortality by 38% compared to placebo in heart failure patients homozygous for the beta1-Arg-389 polymorphism, while Gly-389 carriers derived no survival benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: